Optimizing somatostatin analog therapy in acromegaly: Long-acting formulations

Treatments in Endocrinology

Volumn 1, Issue 3, 2002, Pages 149-154

  Gilroy, John J ^a   James, R Andrew ^a  

^a ROYAL VICTORIA INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; GROWTH HORMONE; GROWTH HORMONE RECEPTOR; LANREOTIDE LA; OCTREOTIDE; OCTREOTIDE LAR; PEGVISOMANT; RECEPTOR SUBTYPE; SOMATOMEDIN C; SOMATOSTATIN 5 RECEPTOR; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG;

ACROMEGALY; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; GROWTH HORMONE RELEASE; HEADACHE; HEALTH CARE COST; HUMAN; HYPOPHYSIS ADENOMA; MORBIDITY; MORTALITY; NURSING; PATIENT SATISFACTION; PRIORITY JOURNAL; RECEPTOR BLOCKING; REVIEW; SWEATING;

ACROMEGALY; CLINICAL TRIALS; DELAYED-ACTION PREPARATIONS; HORMONE ANTAGONISTS; HUMAN GROWTH HORMONE; HUMANS; OCTREOTIDE; PEPTIDES, CYCLIC; SOMATOSTATIN;

EID: 0013126925     PISSN: 11756349     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024677-200201030-00002     Document Type: Review

References (33)

1. Vale W, Brazeau P, Grant G, et al. Premieres observations sur le mode d'action de la somatostatine, un facteur hypothalamique qui inhibe la secretion de l'hormone de croissance. CR Acad Sci (Paris) 1972; 275: 2913-5
2. Brazeau P, Vale W, Burgus R, et al. Hypothalamic polypetide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973; 179: 77-9
3. Krulich L, McCann SM. Effect of GH-releasing factor and GH-inhibiting factor on the release and concentration of GH in pituitaries incubated in vitro. Endocrinology 1969; 85: 319-24
4. Rivier J. Somatostatin: total solid phase synthesis. J Am Chem Soc 1974; 96: 2986-92
5. Coy DH, Coy EJ, Arimura A, et al. Solid phase synthesis of growth hormone-release inhibiting factor. Biochem Biophys Res Commun 1973; 54 (4): 1267-73
6. Hall R, Besser GM, Schally A, et al. Actions of growth hormone release inhibitory hormone in healthy men and in acromegaly. Lancet 1973; 11: 581-4
7. Bauer W, Briner U, Doepfner W, et al. SMS 201-995: a very potent and selective analog of somatostatin with prolonged action. Life Sci 1982; 31: 1133-6
8. James RA, White MC, Chatterjee S, et al. A comparison of octreotide delivered by continuous subcutaneous infusion with intermittent injection in the treatment of acromegaly. Eur J Clin Investig 1992; 22: 554-61
9. Lancranjan I, Bruns C, Grass P, et al. Sandostatin LAR: A promising therapeutic tool in the management of acromegalic patients. Metabolism 1996; 45: 67-71
10. Caron P, Morange-Ramos I, Cogne M, et al. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. J Clin Endocrinol Metab 1997; 82 (1): 18-22
11. Heron I, Thomas F, Dero M, et al. Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analogue BIM 23014 in patients with acromegaly. J Clin Endocrinol Metab 1993; 76 (3): 721-7
12. Gillis JC, Noble S, Goa KL. Octreotide long-acting release (LAR): a review of its pharmacological properties and therapeutic use in the management of acromegaly. Drugs 1997; 53 (4): 681-99
13. Stewart PM. Current therapy for acromegaly. Trends Endocrinol Metab 2000; 11 (4): 128-32
14. Turner HE, Vadivale A, Keenan J, et al. A comparison of lanreotide and octreotide LAR for treatment of acromegaly. Clin Endocrinol 1999; 51 (3): 275-80
15. Davies PH, Stewart SE, Lancranjan I, et al. Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly. Clin Endocrinol 1998; 48: 311-6
16. Stewart PM, James RA. The future of somatostatin analogue therapy. In: Davies JRE, editor. Best practice and research in clinical endocrinology and metabolism. London: Balliere Tindall, 1999; 13 (3): 409-18
17. Kendall-Taylor P, Miller M, Gebbie J, et al. Long-acting octreotide LAR compared with lanreotide SR in the treatment of acromegaly. Pituitary 2000; 3 (2): 61-5
18. Stewart PM, Stewart SE, Clark PM, et al. Clinical and biochemical response following withdrawal of a long-acting, depot injection form of octreotide (Sandostatin-LAR). Clin Endocrinol 1999; 50 (3): 295-9
19. Caron P, Tabarin A, Cogne M, et al. Variable growth hormone profiles following withdrawal of long-term 30mg slow-release lanreotide treatment in acromegalic patients: clinical implications. Eur J Endocrinol 2000; 142: 565-71
20. Jenkins PJ, Akker S, Chew SL, et al. Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration. Clin Endocrinol 2000; 53: 719-24
21. Chanson P, Boerlin V, Ajzenberg C, et al. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly. Clin Endocrinol 2000; 53: 577-86
22. Newman CB, Melmed S, George A, et al. Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab 1998; 83: 3034-49
23. Robbins R. Editorial: Depot somatostatin analogs-a new first line therapy for acromegaly. J Clin Endocrinol Metab 1997; 82 (1): 15-7
24. Giusti M, Gussoni G, Cuttica CM, et al. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. J Clin Endocrinol Metab 1996; 81 (6): 2089-97
25. Lorcy Y, Dejager S, Chanson P. Time course of GH and IGF-1 levels following withdrawal of long-acting octreotide in acromegaly. Pituitary 2000; 3 (3): 193-7
26. Murray RD, Peacey SR, Rahim A, et al. The diagnosis of growth hormone deficiency (GHD) in successfully treated acromegalic patients. Clin Endocrinol 2001; 54 (1): 37-44
27. Cozzi R, Arosio M, Cavagnini F, et al. Lanreotide 60mg in well-controlled acromegalic patients. Pituitary 2000; 3 (1): 27
28. Caron PH, Beckers A, Cullen DR, et al. Efficacy of the new long-acting formulation of lanretide (lanreotide autogel) in the management of acromegaly. J Clin Endocrinol Metab 2002; 87 (1): 99-104
29. Amato G, Mazziotti G, Rotonoi M, et al. Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clin Endocrinol 2002; 56 (1): 65-71
30. Abe T, Ludecke DK. Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre. Eur J Endocrinol 2001; 145: 137-45
31. Blanco-Prieto MJ, Besseghir K, Zerbe O, et al. In vitro and in vivo evaluation of a somatostatin analogue released form PGLA microspheres. J Controlled Release 2000; 67 (1): 19-28
32. Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 2000; 342 (16): 1171-7
33. Reubi JC, Waser B, Schaer JC, et al. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 2001; 28: 836-46